CMV in Pregnancy Selected References


Summary:

- Diagnosis of primary maternal CMV infection in pregnancy should be based on de-novo appearance of CMV specific IgG or on detection of specific IgM antibody associated with low IgG avidity.
- In case of primary maternal infection, risk of uterine transmission and fetal infection is 30-40% and there is a risk of 20-25% for development of sequelae if the fetus is infected.
- The prenatal diagnosis of fetal CMV infection should be based on amniocentesis, which should be done > 7 weeks after maternal infection and after 21 weeks of gestation. This interval is important as it takes 5-7 weeks following fetal infection and subsequent replication of the virus in the kidney for a detectable quantity of virus to be secreted in the amniotic fluid.
- A secondary infection can be suggested by a rise in IgG titer without use of IgM or avidity. Detection and prediction of amniocentesis is not determined with secondary infection due to low rate of fetal infection and sequelae.
- Following diagnosis of fetal CMV infection, recommend US follow up every 2-4 weeks. Absence of sonographic findings does not guarantee a normal outcome.
- Quantitative determination of CMV DNA in AF may assist in predicting outcome.
- Routine screening of pregnant women for CMV by serology testing is currently not recommended.
- Serologic testing for CMV may be considered for women with influenza-like illness during pregnancy or following detection of sonographic findings consistent with CMV infection.
- Seronegative health care and child care workers may be offered serologic monitoring during pregnancy. Monitoring may also be considered for seronegative pregnant women who have a young child in day care.


Sens/spec of IgG avidity for detect primary maternal infection

<table>
<thead>
<tr>
<th>Reference</th>
<th>Before weeks' EGA</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lazzarotto, 1997</td>
<td>16-18</td>
<td>92.8%</td>
<td>85.7%</td>
</tr>
<tr>
<td>Eggers, 2000</td>
<td>20</td>
<td>-----</td>
<td>100%</td>
</tr>
</tbody>
</table>
Grangeot-Keros and Conte, 2001
---
Bodeus, 2001
---
Revello, 2004
---

<table>
<thead>
<tr>
<th>Maternal Infection</th>
<th>Total</th>
<th>IgM positive</th>
<th>Avidity (low/moderate)</th>
<th>Avidity (high)</th>
<th>Congenital infection (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not active</td>
<td>1367</td>
<td>0</td>
<td>0</td>
<td>1367</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>Primary true IgM + low/mod avidity</td>
<td>514</td>
<td>514</td>
<td>514</td>
<td>0</td>
<td>53 (30.3)</td>
</tr>
<tr>
<td>Primary serocconversion</td>
<td>183</td>
<td>183</td>
<td>183</td>
<td>0</td>
<td>6 (2)</td>
</tr>
<tr>
<td>Non-primary</td>
<td>336</td>
<td></td>
<td></td>
<td>336</td>
<td>6 (2)</td>
</tr>
<tr>
<td>Undefined</td>
<td>77</td>
<td>77</td>
<td>65 (all mod)</td>
<td>12</td>
<td>3 (4.7)</td>
</tr>
</tbody>
</table>

Prediction of congenital infection based on amniotic fluid viral detection:

* of 111 positive AF PCR, 22 fetus with <500 copies, all asymptomatic at birth and 9 normal at 6 years, 10 normal at 1-5 years, 3 normal at 6 months

* Prediction of congenital CMV infection based on q PCR copies/ml
>500 Sensitivity 80.2%; Specificity 100%; PPV 100%; NPV 94.2%

* AF viral load < 10^3 low risk of symptomatic infection

Prediction of congenital infection (positive urine CMV at birth)

Table adapted from Lazzarotto, 2008

650 fetuses with mothers with serological evidence of primary infection, with congenital infection defined as positive urine at birth, US findings found in 23 of 154 congenitally infected fetuses (14.9%)
When fetal infection status is unknown, ultrasound abnormalities predict symptomatic infection in only a third of cases

- Abnormal US prediction of congenital infection:
  - Sensitivity: 14.93%; specificity 93.72%; PPV 45.1%; NPV 76.1%

- Abnormal US prediction of symptomatic congenital infection
  - Sensitivity: 20.9%; specificity 93.57%; PPV 35.3%; NPV 87.6%

Abnormal US finding in all fetuses from mothers with primary CMV infection demonstrated PPV of 35% for symptomatic infection
48% probability that a normal US excluded development of symptomatic fetal infection

Prevention of CMV infection in women who are or will become pregnant

- Educate women with young children/work with young children that they are at increased risk
- Attention to hygiene will help prevent CMV transmission
- Careful handling of potentially infected articles (diapers)
- Hand washing around young children
- Avoid sharing utensils
- Avoid kissing children < 6 years on the mouth or cheek


- HIG did not reduce the risk of fetal infection following maternal primary CMV infection
- the risk of infection was 30% among those receiving HIG and 44% among those receiving placebo (P = 0.13)
12) SMFM Consult Series. Diagnosis and management of congenital cytomegalovirus infection.

- We do not recommend antenatal treatment with ganciclovir or valacyclovir; and we recommend that any antenatal therapy, either with antivirals or CMV HIG, should only be offered as part of a research protocol.
- We do not recommend routine screening of all pregnant women for evidence of primary CMV infection at this time.
- For women suspected of having primary CMV infection in pregnancy, we recommend that diagnosis should be either by IgG seroconversion or with positive CMV IgM, positive IgG, and low IgG avidity.
- Amniocentesis is the best option as a prenatal diagnostic tool to detect fetal congenital CMV infection, performed >21 weeks of gestation and >6 weeks from maternal infection.
- We do not recommend antenatal treatment with ganciclovir or valacyclovir; and we recommend that any antenatal therapy, either with antivirals or CMV hyperimmune globulin, should only be offered as part of a research protocol.


- Routine serologic screening of pregnant women for CMV is not recommended.